Clinical Trial Detail

NCT ID NCT02379390
Title Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enz (PRIMCAB)
Recruitment Terminated
Gender male
Phase Phase II
Variant Requirements No
Sponsors Sanofi
Indications

prostate adenocarcinoma

Therapies

Prednisone

Abiraterone

Enzalutamide

Cabazitaxel

Age Groups: adult

No variant requirements are available.